MX2009008022A - Metodos y composiciones para tratar neuropatias. - Google Patents

Metodos y composiciones para tratar neuropatias.

Info

Publication number
MX2009008022A
MX2009008022A MX2009008022A MX2009008022A MX2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A
Authority
MX
Mexico
Prior art keywords
methods
activity
treating
neuropathies
compositions
Prior art date
Application number
MX2009008022A
Other languages
English (en)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2009008022A publication Critical patent/MX2009008022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para tratar o prevenir la degradación axonal en enfermedades neuropáticas y trastornos neurológicos en mamíferos; los métodos pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa, por lo menos en parte, aumentando la actividad sirtuinAMPK, la actividad LKB 1 y/o la actividad CaMKKß en neuronas enfermas y/o lesionadas; los métodos también pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa aumentando la cavidad de NAD en neuronas enfermas y/o lesionadas, solo o en combinación con agentes que actúan por otros mecanismos; también se describen métodos para analizar agentes para el tratamiento de neuropatías y vectores recombinantes para el tratamiento o la prevención de dichas neuropatías.
MX2009008022A 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias. MX2009008022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88685407P 2007-01-26 2007-01-26
PCT/US2008/001085 WO2008091710A2 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
MX2009008022A true MX2009008022A (es) 2009-12-11

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008022A MX2009008022A (es) 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias.

Country Status (5)

Country Link
US (3) US20100047177A1 (es)
EP (1) EP2124985A4 (es)
CA (1) CA2676609A1 (es)
MX (1) MX2009008022A (es)
WO (1) WO2008091710A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259782A4 (en) 2008-03-03 2013-01-23 Nad Life Pty Ltd PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES
EP2323649A4 (en) * 2008-07-25 2011-09-07 Univ Emory TREATMENT OF VARIOUS DISORDERS WITH 7,8-DIHYDROXY FLAVONE AND ITS DERIVATIVES
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Ｌｋｂ１活性化剤
CA2801415A1 (en) 2010-06-09 2011-12-15 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP4233878A1 (en) 2013-03-15 2023-08-30 Washington University Administration of nicotinamide mononucleotide in the treatment of dry eye
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
EP3152220A1 (en) 2014-06-06 2017-04-12 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016144660A1 (en) 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US20170068860A1 (en) * 2015-09-09 2017-03-09 Alex Adekola System for measuring crowd density
US20190203207A1 (en) * 2016-05-20 2019-07-04 The Trustees Of Columbia University In The City Of New York Anabolic Enhancers for Ameliorating Neurodegeneration
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
WO2019126482A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
JP2022523702A (ja) 2019-01-28 2022-04-26 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
IT202000007726A1 (it) * 2020-04-10 2021-10-10 Solongevity Nutraceuticals S R L Composizioni mimetiche della restrizione calorica
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
EP4297800A1 (en) * 2021-02-26 2024-01-03 Icahn School of Medicine at Mount Sinai Method for decreasing degeneration of retinal ganglion cells
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
WO2024170772A1 (en) * 2023-02-17 2024-08-22 Mim Neurosciences Ab Epigallocatechin-3-gallate (egcg) analogs for use in the treatment of diseases in which an increase of nad+ is beneficial such as glaucoma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3872399A (en) * 1998-04-28 1999-11-16 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
AU5446900A (en) * 1999-05-28 2000-12-18 Immunex Corporation Novel murine and human kinases
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
AU2003268235A1 (en) * 2002-09-09 2004-03-29 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005004814A2 (en) * 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
AU2004312072B2 (en) * 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2555675A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
DK1755391T3 (en) * 2004-06-04 2016-02-08 Univ Washington METHODS AND COMPOSITIONS FOR THE TREATMENT OF neuropathies
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
EP1762234A4 (en) * 2004-06-28 2010-05-05 Kao Corp AMPK AKTIVATOR
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CA2613141A1 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
ES2396913T3 (es) * 2005-08-04 2013-03-01 Sirtris Pharmaceuticals, Inc. Compuestos moduladores de sirtuina
KR101460820B1 (ko) * 2007-01-16 2014-11-11 아이피아이엔티엘, 엘엘씨 대사 증후군의 치료를 위한 신규한 조성물

Also Published As

Publication number Publication date
WO2008091710A3 (en) 2008-10-09
CA2676609A1 (en) 2008-07-31
US20100047177A1 (en) 2010-02-25
US20140011890A1 (en) 2014-01-09
US20160367497A1 (en) 2016-12-22
EP2124985A2 (en) 2009-12-02
EP2124985A4 (en) 2011-06-08
WO2008091710A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
WO2006001982A3 (en) Methods and compositions for treating neuropathies
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
HRP20130707T1 (en) Compositions and uses for treating multiple sclerosis
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
WO2005000331A3 (en) Compositions for the treatment and prevention of degenerative joint disorders
WO2007040565A3 (en) Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
TN2012000270A1 (en) Methods and low dose regimens for treating red blood cell disorders
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
EP3150635A3 (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007022470A3 (en) Methods and compositions for treating neurological disease
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
MX2007003271A (es) Derivados de purina y metodos de uso de los mismos.
WO2006078574A3 (en) Mitotic kinesin inhibitors
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
WO2006086693A3 (en) Medical devices
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal